765 related articles for article (PubMed ID: 28011467)
1. Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
Nguyen AH; Detty SQ; Agrawal DK
Anticancer Res; 2017 Jan; 37(1):1-7. PubMed ID: 28011467
[TBL] [Abstract][Full Text] [Related]
2. Ousting RAGE in melanoma: A viable therapeutic target?
Syed DN; Aljohani A; Waseem D; Mukhtar H
Semin Cancer Biol; 2018 Apr; 49():20-28. PubMed ID: 29079306
[TBL] [Abstract][Full Text] [Related]
3. RAGE Signaling in Melanoma Tumors.
Olaoba OT; Kadasah S; Vetter SW; Leclerc E
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256110
[TBL] [Abstract][Full Text] [Related]
4. The HMGB1/RAGE Pro-Inflammatory Axis in the Human Placenta: Modulating Effect of Low Molecular Weight Heparin.
Zenerino C; Nuzzo AM; Giuffrida D; Biolcati M; Zicari A; Todros T; Rolfo A
Molecules; 2017 Nov; 22(11):. PubMed ID: 29149067
[TBL] [Abstract][Full Text] [Related]
5. Clinical use of high mobility group box 1 and the receptor for advanced glycation end products in the prognosis and risk stratification of heart failure: a literature review.
Marsh AM; Nguyen AH; Parker TM; Agrawal DK
Can J Physiol Pharmacol; 2017 Mar; 95(3):253-259. PubMed ID: 28092162
[TBL] [Abstract][Full Text] [Related]
6. The myocardial infarct-exacerbating effect of cell-free DNA is mediated by the high-mobility group box 1-receptor for advanced glycation end products-Toll-like receptor 9 pathway.
Tian Y; Charles EJ; Yan Z; Wu D; French BA; Kron IL; Yang Z
J Thorac Cardiovasc Surg; 2019 Jun; 157(6):2256-2269.e3. PubMed ID: 30401529
[TBL] [Abstract][Full Text] [Related]
7. Critical role of RAGE and HMGB1 in inflammatory heart disease.
Bangert A; Andrassy M; Müller AM; Bockstahler M; Fischer A; Volz CH; Leib C; Göser S; Korkmaz-Icöz S; Zittrich S; Jungmann A; Lasitschka F; Pfitzer G; Müller OJ; Katus HA; Kaya Z
Proc Natl Acad Sci U S A; 2016 Jan; 113(2):E155-64. PubMed ID: 26715748
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.
Ren L; Lou Y; Sun M
Bioengineered; 2021 Dec; 12(1):5985-5995. PubMed ID: 34477479
[TBL] [Abstract][Full Text] [Related]
9. HMGB1/RAGE pro-inflammatory axis promotes vascular endothelial cell apoptosis in limb ischemia/reperfusion injury.
Mi L; Zhang Y; Xu Y; Zheng X; Zhang X; Wang Z; Xue M; Jin X
Biomed Pharmacother; 2019 Aug; 116():109005. PubMed ID: 31136947
[TBL] [Abstract][Full Text] [Related]
10. UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer.
Liu-Smith F; Jia J; Zheng Y
Adv Exp Med Biol; 2017; 996():27-40. PubMed ID: 29124688
[TBL] [Abstract][Full Text] [Related]
11. Anti-high-mobility group box-1 (HMGB1) mediates the apoptosis of alveolar epithelial cells (AEC) by receptor of advanced glycation end-products (RAGE)/c-Jun N-terminal kinase (JNK) pathway in the rats of crush injuries.
Zhang BF; Song W; Wang J; Wen PF; Zhang YM
J Orthop Surg Res; 2022 Jan; 17(1):20. PubMed ID: 35033142
[TBL] [Abstract][Full Text] [Related]
12. The Immune Tolerance Role of the HMGB1-RAGE Axis.
Watanabe H; Son M
Cells; 2021 Mar; 10(3):. PubMed ID: 33807604
[TBL] [Abstract][Full Text] [Related]
13. Trimebutine attenuates high mobility group box 1-receptor for advanced glycation end-products inflammatory signaling pathways.
Nakajima S; Ogawa N; Yokoue N; Tachibana H; Tamada K; Okazawa M; Sato A; Oyama T; Abe H; Kamiya T; Yoshimori A; Yoshizawa K; Inoue S; Yokomizo T; Uchiumi F; Abe T; Tanuma SI
Biochem Biophys Res Commun; 2020 Dec; 533(4):1155-1161. PubMed ID: 33041002
[TBL] [Abstract][Full Text] [Related]
14. HMGB1 mediates HAdV-7 infection-induced pulmonary inflammation in mice.
Tang Z; Zang N; Fu Y; Ye Z; Chen S; Mo S; Ren L; Liu E
Biochem Biophys Res Commun; 2018 Jun; 501(1):1-8. PubMed ID: 29571731
[TBL] [Abstract][Full Text] [Related]
15. High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.
Ge X; Arriazu E; Magdaleno F; Antoine DJ; Dela Cruz R; Theise N; Nieto N
Hepatology; 2018 Dec; 68(6):2380-2404. PubMed ID: 29774570
[TBL] [Abstract][Full Text] [Related]
16. High-Mobility Group Box 1 (HMGB1) Induces Migration of Endothelial Progenitor Cell via Receptor for Advanced Glycation End-Products (RAGE)-Dependent PI3K/Akt/eNOS Signaling Pathway.
Zhang Y; You B; Liu X; Chen J; Peng Y; Yuan Z
Med Sci Monit; 2019 Aug; 25():6462-6473. PubMed ID: 31461437
[TBL] [Abstract][Full Text] [Related]
17. Molecular signaling of the HMGB1/RAGE axis contributes to cholesteatoma pathogenesis.
Szczepanski MJ; Luczak M; Olszewska E; Molinska-Glura M; Zagor M; Krzeski A; Skarzynski H; Misiak J; Dzaman K; Bilusiak M; Kopec T; Leszczynska M; Witmanowski H; Whiteside TL
J Mol Med (Berl); 2015 Mar; 93(3):305-14. PubMed ID: 25385222
[TBL] [Abstract][Full Text] [Related]
18. HMGB1 Enhances the AGE-Induced Expression of CTGF and TGF-β via RAGE-Dependent Signaling in Renal Tubular Epithelial Cells.
Cheng M; Liu H; Zhang D; Liu Y; Wang C; Liu F; Chen J
Am J Nephrol; 2015; 41(3):257-66. PubMed ID: 25924590
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential of Targeting the HMGB1/RAGE Axis in Inflammatory Diseases.
Singh H; Agrawal DK
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364135
[TBL] [Abstract][Full Text] [Related]
20. Ketamine attenuates sepsis-induced acute lung injury via regulation of HMGB1-RAGE pathways.
Li K; Yang J; Han X
Int Immunopharmacol; 2016 May; 34():114-128. PubMed ID: 26945830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
